Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes
Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite th
| Condition(s) | Overactive Bladder (OAB) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall mechanical work output of the bladder during micturition. To address this question, our research proposes to assess how mirabegron, solifenacin, and BoNTA influence bladder function from a thermodynamic perspective. We will apply pressure-volume analysis (PVA), a m |
| Who can participate | Inclusion Criteria: \- female overactive bladder Exclusion Criteria: * DM, CVA, other medical problems |
| Ages | 30 Years to 100 Years |
| Sex | Female |
| Lead sponsor | Mackay Medical College |
| Locations | New Taipei City, Taiwan |
| Start date | 2025-07-01 |
| NCT ID | NCT07025642 |
| Official listing | https://clinicaltrials.gov/study/NCT07025642 |